乳がんの治療方針を決める因子🧬

Stage I〜IIIAの早期乳がんで薬物療法を行う場合、

・エストロゲン受容体
・HER2
・OncotypeDX
・BRCA1/2
・PD-L1

これらによって、患者さんごと適した薬剤、治療方法が異なってきます

なぜこの薬で治療しているのか？

これらの要因があることを知ってください⭕️

#asbrs22 oncotypedx on core perfectly acceptable

#TILS #TLSA ⏳💣
•AGM Thursday 10am
•stemprintER spin-off deal could push towards $1b 🤔

🧪Foralumab ~ $27 billion market
🌡Milciclib ~ $18 billion market size
🧫Anti IL-6r ~ $32 billion market
🧬StemPrint ER ~ 30% superiority over market leader OncotypeDX

Kunwar Shailubhai values #TILS in the $billions 💰💰💰
•stemprintER spin-off value could push towards $1b 🤔

👩🏼‍🔬Foralumab ~ $27 billion market
🧑🏾‍🔬Milciclib ~ $18 billion market size
🧑🏼‍🔬Anti IL-6r ~ $32 billion market
👩🏽‍🔬StemPrint ER ~ 30% superiority over market leader OncotypeDX

Great talk by Olga Kantor MD, MS, FACS on using OncotypeDx in the neoadjuvent setting! UChicago Surgery @NorthShoreWeb #ASBrS19

2021年12月7日付けにて、日本乳癌学会からも
#株式会社エスアールエル
並びに
#エグザクトサイエンス株式会社
に対して、 #OncotypeDX Breastに関する要望書が提出されました。両企業は速やかに検査受託の再開と実施体制の整備を進めることを重ねて要望させて頂きます。

jbcs.gr.jp/modules/info/i…

If you’ve been recently diagnosed with early stage, estrogen receptor-positive (ER+) HER2-negative (HER2-) #breastcancer , the #OncotypeDX test can help you and your doctor understand what treatment options are right for you-including Chemo oncotypeiq.com/en-US/about/ab…
My test results:

🧬: Can OncotypeDX & MammaPrint predict pCR after neoadjuvant chemo?
🧬Largest study on multigene assays & pCR
🧬OncotypeDX: High RS linked to greater odds of pCR
🧬MammaPrint: High scores more likely to achieve pCR
🧬May help tailor treatment in neo-adjuvant settings and…

Magee Equation in selecting patients requests for oncotypeDX. #pathology #ASDP18 #Pathologists #ASCP #ASDP18 #ASCyto18 #breastcancer

#TILS $TLSA some slide highlights. Absolutely huge upside. Growth pipeline is mega. #COVID19 #Cancer #MultipleSclerosis market leader OncotypeDX which was bought for $2.8billion isn’t the new #breastcancer leading treatment. StemprintER is 40-45% better. What a company

Use of OncotypeDX for Her2 testing may exclude incorrectly patients eligible for Herceptin— instead use CAP/ASCO guidelines with IHC/FISH —Dr. Gary Tozbikian ⁦@OSUPathRes⁩ #her2 #breastcancer

Was recently shown OncotypeDx report @OncotypeIQ for a breast patient. At least four inconsistencies in this one report: A) different risk groupings; B) no incorporation of clinical factors in risk estimates; C) 3 different endpoints; D) 95% CI without central estimate.

Retweeted ASBrS (ASBrS):

Women age <50 have higher rates of chemotherapy recommendation than those >50 in every OncotypeDX recurrence score category - NCDB analysis shows
#ASBrS18 Austin D. Williams, MD MSEd; @Lucy M. De La Cruz MD; PennSurgery

New strategies for decision making in #prostatecancer The role of oncotypedx elsevier.es/es-revista-act…

#TailorX subgroup analysis suggesting the need for a specific design addressing #premenopausal & #young women plus possible substratification of oncotypeDX scores: a door closed, many windows opened. #ASCO18

Single curve, could not be clearer. OncotypeDX RS is now a binary test. Endocrine therapy for score 25 or less #ASCO18 Mayo Clinic Comprehensive Cancer Center

Excellent presentation by Kyra Nicholson, MD, MSPH on OncotypeDx scores and nodal status in older patients. Factors associated w/ high scores - grade 3, PR neg, large tumor size. Number of nodes not associated. UChicago Surgery @NorthShoreWeb #ASBrS22 ASBrS UChicago Surgery Residents Jeff Matthews MD

MARCH ISSUE: #OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative #BreastCancer Patients.ow.ly/ZbDh30nOpyD Kelly McMasters, MD, PhD Society of Surgical Oncology

A fantastic presentation by Olga Kantor MD, MS, FACS on use of OncotypeDx recurrence score in patients receiving neoadjuvant chemotherapy #ASBrS19 #bcsm ASBrS UChicago Surgery @NorthShoreWeb

Disminución de 3/4 en reducción de costos con el uso de OncotypeDx en un estudio canadiense academic.oup.com/oncolo/advance…